Clinical Trial Update: Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura [Phase 2]

View source ↗

Summary

Phase 2 trial updating efficacy and safety of a 10% triple virally reduced intravenous immunoglobulin in adults with chronic immune thrombocytopenic purpura (IT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• 10% Triple Virally Reduced Intravenous Immunoglobulin Solution (intravenous immunoglobulin)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Immune Thrombocytopenic Purpura (ITP) | Phase 2 | Status: COMPLETED